{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T05:16:34Z","timestamp":1698124594448},"reference-count":11,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T00:00:00Z","timestamp":1205712000000},"content-version":"vor","delay-in-days":5829,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1992,4]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p> <jats:sc>objective<\/jats:sc> The objective of this study was to assess the relationship of different doses of a long\u2010acting bromocriptine preparation (Pariodel LAR) to the degree and duration of PRL suppression. We also measured circulating bromocriptine levels and altered tolerability of the drug<\/jats:p><jats:p> <jats:sc>design<\/jats:sc> A double\u2010blind randomized study of three different doses 25, 50 and 100 mg of Pariodel LAR<\/jats:p><jats:p> <jats:sc>patients<\/jats:sc> Twenty\u2010one female patients (seven patients\/dose) with both tumoral and non\u2010tumoral hyperproiactinaemia<\/jats:p><jats:p> <jats:sc>measurements<\/jats:sc> After a single injection of Parlodel LAR 25, 50 or 100 mg, serum PRL and plasma bromocrlptlne levels were assessed during a follow\u2010up of 60 days together with changes in clinical symptoms and signs of hyperproiactinaemia<\/jats:p><jats:p> <jats:sc>results<\/jats:sc> Serum PRL levels normailzed In 19 of 21 patients. The suppression of PRL secretion lasted 28 days in four of seven patients treated with either 25 or 50 mg Parlodei LAR and in five of seven patients who received Parlodel LAR 100 mg. In five of seven patients treated with the 100 mg dose, serum PRL levels were still within the normal range on day 60. Plasma bromocriptine levels remained therapeutically active for 28 days in all three groups. On day 60 they were within the therapeutic range only in the 100 mg group. Clinical data show a rapid disappearance of symptoms and signs of hyperprolactlnaemla. Adverse events were mostly mild and transient<\/jats:p><jats:p> <jats:sc>conclusions<\/jats:sc> These data support the excellent efficacy and good tolerability of Pariodel LAR in patients with hyperproiactinaemia<\/jats:p>","DOI":"10.1111\/j.1365-2265.1992.tb01462.x","type":"journal-article","created":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T11:41:42Z","timestamp":1205754102000},"page":"369-374","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of a new long\u2010acting injectable form of bromocriptine in hyperprolactinaemic patients"],"prefix":"10.1111","volume":"36","author":[{"given":"M. D.","family":"Paganl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Tengattini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Montini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pedroncelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Gianola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Gherardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Mazzocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Lancranjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,17]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"833","volume-title":"Prolactin. Basic and Clinical Correlates","author":"Besser G.M.","year":"1985"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)53154-9"},{"key":"e_1_2_1_4_1","first-page":"555","volume-title":"Pain and Reproduction","author":"Lancranjan I.","year":"1988"},{"key":"e_1_2_1_5_1","first-page":"231","volume-title":"Lisuride and Other Dopamine Agonists","author":"Liuzzi A.","year":"1983"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-60-4-698"},{"key":"e_1_2_1_7_1","first-page":"305","volume-title":"Recent Research on Gynecological Endocrinology","author":"Montini M.","year":"1989"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-4484-1_25"},{"key":"e_1_2_1_9_1","first-page":"125","volume-title":"Neuroendocrine and Neuropsychiatric Aspects","author":"Schran H.F.","year":"1980"},{"key":"e_1_2_1_10_1","first-page":"213","volume-title":"Lisuride and Other Dopamine Agonists","author":"Thorner M.O.","year":"1983"},{"key":"e_1_2_1_11_1","first-page":"51","article-title":"Primary treatment of macroprolactinomas with Parlodel LAR","volume":"119","author":"Verlaat J.","year":"1988","journal-title":"Acta Endocrinotogica"},{"key":"e_1_2_1_12_1","first-page":"27","volume-title":"Advances in Gynecological Endocrinology","author":"Werder K.","year":"1988"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.1992.tb01462.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.1992.tb01462.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T20:06:58Z","timestamp":1698091618000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.1992.tb01462.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,4]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1992,4]]}},"alternative-id":["10.1111\/j.1365-2265.1992.tb01462.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.1992.tb01462.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,4]]}}}